XKRX
220100
Market cap121mUSD
Oct 08, Last price
7,040.00KRW
1D
-0.14%
1Q
-3.57%
IPO
-22.52%
Name
FutureChem Co Ltd
Chart & performance
P/E
—
P/S
8.74
EPS
—
Div yield, %
—
Shrs. gr., 5y
15.47%
Rev. gr., 5y
11.13%
Revenues
18.67b
+7.96%
Net income
-11.25b
L+19.47%
CFO
-2.43b
L-24.36%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
FutureChem Co.,Ltd is a South Korean company dedicated to the creation and distribution of radiopharmaceutical products. Its current offerings include PDVUE, a positron emission tomography (PET) diagnostic agent for Parkinson's disease; Alzavue, used in the diagnosis of Alzheimer's disease; and [18F]FDG, a PET radiopharmaceutical primarily employed in cancer therapy. The company's development pipeline is robust, featuring 18F-FC303, a PET diagnostic for prostate cancer; 177Lu-FC705, targeting prostate cancer treatment; 18F-FMT, aimed at brain tumors; 18F-FC505, designed for atherosclerotic plaque; and 18F-FC211, another prospective treatment for Alzheimer's disease. Founded in 1999, FutureChem Co.,Ltd is headquartered in Seoul, South Korea.
Key people
Yeong Ja Park
Managing Director
Cheol Kim
Internal Auditor · since 2017
Hui Seop Gil
Chief Technology Officer, Assistant Managing Director
Dae Yun Ji
President, Chief Executive Officer, Director
Yeong Yil Yoo
Chief Financial Officer, Assistant Managing Director · since 2020
Hun Ma
Other Non-Executive Director · since 2019
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||